Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma
Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma
复制标题
DOI：
10.1093/annonc/mdr157
复制
发表时间：
2012-03-01
影响因子：
50.5
通讯作者：
Spector, N.
中科院分区：
文献类型：
--
作者：
Azambuja, D.;Natkunam, Y.;Spector, N.
背景资料：最近的一项研究表明，CD 68+巨噬细胞数量的增加与经典霍奇金淋巴瘤（cHL）患者的原发性治疗失败、缩短的无进展生存期（PFS）和疾病特异性生存期（DSS）相关。患者和方法：本研究的目的是验证CD 68+和CD 163+数量之间的关系，在265例充分表征的cHL患者队列中，使用标准多柔比星、博来霉素、长春碱和达卡巴嗪化疗方案统一治疗，两对血液病理学家进行了独立的病理组织芯片slide.Results评价：有没有临床特征和表达的CD 68或CD 163之间的关联。然而，更高水平的CD68和CD163表达与EB病毒阳性霍奇金肿瘤细胞的存在相关（P = 0.01和0.037，分别）。CD68和CD163的表达与PFS和DSS均无相关性。结论：CD68和CD163的表达在用于cHL患者的预后分层之前需要进一步评估。
Background: A recent study demonstrated that an increased number of CD68+ macrophages were correlated with primary treatment failure, shortened progression-free survival (PFS) and disease-specific survival (DSS) in patients with classical Hodgkin's lymphoma (cHL).Patients and methods: The aim of the present study was to verify the relationship between the number of CD68+ and CD163+ macrophages with clinical outcomes in a cohort of 265 well-characterized patients with cHL treated uniformly with the standard doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen. Two pairs of hematopathologists carried out independent pathological evaluations of tissue microarray slides.Results: There were no associations between clinical characteristics and the expression of CD68 or CD163. However, higher levels of CD68 and CD163 expression were correlated with the presence of Epstein-Barr virus-positive Hodgkin tumor cells (P = 0.01 and 0.037, respectively). The expression of CD68 or CD163 was not associated with either the PFS or the DSS.Conclusion: CD68 and CD163 expression require further evaluation before their use can be recommended for prognostic stratification of patients with cHL.